摘要
目的评价AML-XH-99-M3方案治疗儿童急性早幼粒细胞白血病(M3)疗效。方法33例M3患儿接受AML-XH-99-M3方案治疗,应用Kaplan-Meier方法进行生存分析,评估患儿的无事生存期(EFS)、无疾病生存期(DFS)及总生存期(OS),所有数据采用SPSS13.0软件统计。结果33例患儿30例(90.9%)一个疗程达完全缓解(CR),余3例二个疗程CR,总CR率为100%,复发6例(18.2%),平均复发时间为29(16～38)个月,死亡2例(6.1%),7年EFS和DFS均为(73.4±9.4)%,总OS为(91.2±6.0)%,维持治疗中间歇加用全反式维甲酸(ATRA)和无ATRA两组EFS差异有统计学意义,分别为(88.9±10.5)%和(62.5±13.6)%(P<0.05)。结论AML-XH-99-M3方案治疗儿童M3获得了很好的CR率,具有较高的EFS、DFS和OS,维持治疗中加用ATRA可明显降低复发率、提高EFS。
Objective To evaluate the effectiveness of AML-XH-99-M3 protocol for treatment of acute promyelocytic leukemia （APL） in children. Methods Thirty-three children with APL received AML-XH-99-M3 protocol treatment. The event-free survival （EFS）, disease-free survival （DFS） , and overall survival （OS） were evaluated by the Kaplan-Meier medthod with SPSS13.0 software. Results Thirty patients （ 90.9% ） achieved a complete remission （ CR ） after one course of treatment. The total CR rate was 100%. Six patients （18.2%） relapsed in an average of 29.17 months （16-38 months）. Two patients （ 6. 1% ） died. The 7-year EFS and DFS in the 30 patients were 73.4 ± 9.4%. The overall survival rate was 91.2 ± 6.0%. The difference of EFS was observed in patients receiving intermittent all-trans-retinoic acid （ATRA） administration or not in the maintenance therapy （ 88.9 ± 10.5% vs 62.5 ± 13.6% ） （ P 〈 0.05 ）. Conclusions The AML-XH-99-M3 protocol for the treatment of APL produced a higher CR rate and higher EFS, DFS and OS rates in children. Intermittent administration of ATRA in the maintenance therapy can improve EFS rate.
出处
《中国当代儿科杂志》
CAS
CSCD
2008年第3期329-332,共4页
Chinese Journal of Contemporary Pediatrics
关键词
急性早幼粒细胞白血病
治疗方案
疗效
儿童
Acute promyelocytic leukemia
Treatment protocol
Effectiveness
Child
